Literature DB >> 1376187

[RP 67580, a potent and selective substance P non-peptide antagonist].

C Garret1, A Carruette, V Fardin, S Moussaoui, J F Peyronel, J C Blanchard, P M Laduron.   

Abstract

The pharmacological properties of 7,7-Diphenyl-2 [1-imino-2 (2-methoxy-phenyl)-ethyl] perhydroisoindol-4-one (3 aR, 7 aR) or RP67580 are described. This compound, derived from a novel chemical family, is a potent and selective substance P (SP) antagonist, in vitro and in vivo. In vitro, it inhibited in a competitive manner (IC50 = 10 nM) 3H-SP binding in rat brain (NK1 receptors). It did not interact with the two other tachykinin receptor sites (NK2 and NK3) nor the other receptor sites tested. Moreover, RP67580 competitively antagonized the contractile activity of SP on guinea-pig ileum (pA2 = 7.16); in contrast, it was inactive in rabbit pulmonary artery and in rat portal vein tissues which contain NK2 and NK3 receptors, respectively. In vivo, in the rat, RP67580 inhibited the plasmatic extravasation induced by administration of SP (ED50 = 0.04 mg/kg i.v.) as well as that induced by antidromic stimulation of a peripheral sensory nerve (ED50 = 0.15 mg/kg i.v.). In mice and rats, RP67580, like morphine, potently blocked the nociceptive effects of phenylbenzoquinone and formalin; its antinociceptive effect does not involve opiate receptors since it was not reversed by naloxone. These results indicate that RP67580 is a particularly valuable tool for investigating the physiological and pathological role of SP.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1376187

Source DB:  PubMed          Journal:  C R Acad Sci III        ISSN: 0764-4469


  7 in total

1.  Central versus peripheral site of action of the tachykinin NK1-antagonist RP 67580 in inhibiting chemonociception.

Authors:  U Holzer-Petsche; T Rordorf-Nikolić
Journal:  Br J Pharmacol       Date:  1995-06       Impact factor: 8.739

2.  Cardiovascular responses to intrathecal neuropeptide gamma in conscious rats: receptor characterization and mechanism of action.

Authors:  P Poulat; J de Champlain; R Couture
Journal:  Br J Pharmacol       Date:  1996-01       Impact factor: 8.739

3.  Inflammation-induced abnormalities in the subcellular localization and trafficking of the neurokinin 1 receptor in the enteric nervous system.

Authors:  Daniel P Poole; TinaMarie Lieu; Juan Carlos Pelayo; Emily M Eriksson; Nicholas A Veldhuis; Nigel W Bunnett
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2015-07-02       Impact factor: 4.052

4.  Endothelin-converting enzyme-1 regulates trafficking and signalling of the neurokinin 1 receptor in endosomes of myenteric neurones.

Authors:  Juan-Carlos Pelayo; Daniel P Poole; Martin Steinhoff; Graeme S Cottrell; Nigel W Bunnett
Journal:  J Physiol       Date:  2011-08-30       Impact factor: 5.182

5.  Cardiovascular and behavioural effects of centrally administered tachykinins in the rat: characterization of receptors with selective antagonists.

Authors:  P Picard; D Regoli; R Couture
Journal:  Br J Pharmacol       Date:  1994-05       Impact factor: 8.739

6.  Cardiovascular and behavioural effects of centrally administered neuropeptide K in the rat: receptor characterization.

Authors:  A Prat; P Picard; R Couture
Journal:  Br J Pharmacol       Date:  1994-05       Impact factor: 8.739

7.  Modulation of dopamine D1 receptors via histamine H3 receptors is a novel therapeutic target for Huntington's disease.

Authors:  David Moreno-Delgado; Mar Puigdellívol; Silvia Ginés; Peter J McCormick; Estefanía Moreno; Mar Rodríguez-Ruiz; Joaquín Botta; Paola Gasperini; Anna Chiarlone; Lesley A Howell; Marco Scarselli; Vicent Casadó; Antoni Cortés; Sergi Ferré; Manuel Guzmán; Carmen Lluís; Jordi Alberch; Enric I Canela
Journal:  Elife       Date:  2020-06-09       Impact factor: 8.140

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.